Gainplan’s NovoCure NVCR Stock Holding History

Gainplan’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2,000	Closed	-$223K	–	53
2020 Q3	$223K	Buy	+2,000	New	+$160K	0.33%	32

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Gainplan's NVCR Position: Q4 2020 in Review

Gainplan sold out of NovoCure (NVCR) in Q4 2020, closing a stake of 2,000 shares — an estimated $223K sold.

Gainplan first reported a position in NVCR in Q3 2020 and held it in 1 quarter. The position peaked at $223K in Q3 2020. 357 funds tracked by Wall St. Rank hold NVCR as of Q4 2020.

Gainplan reported no remaining NovoCure position as of Q4 2020 after selling out during the quarter.
Gainplan sold 2,000 NovoCure shares in Q4 2020, an estimated $223K.
Gainplan first reported a position in NovoCure in Q3 2020 and held it in 1 quarter.
Gainplan's NovoCure position peaked at $223K in Q3 2020.
357 funds tracked by Wall St. Rank held NovoCure as of Q4 2020.

Based on Gainplan's 13F filing for Q4 2020, filed 10 Feb 2021.